Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AND017 Phase II in IPSS-R lower-risk myelodysplastic syndrome anemia
ChiCTR2500106742Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AND017 in myelodysplastic syndrome (MDS), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Hemoglobin level and related hematologic indicators. Started Jul 2025; status: recruiting.
02
Drugs
AND017
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2500106742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106742.